 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Name:
|
Eptastigmine
|
|
Other Names:
|
MF 201
|
|
Development Status:
|
investigational in U.S.
|
|
FDA Phase:
|
Discontinued
|
|
Primary Medical Role:
|
Prevent cognitive deterioration in AD.
|
|
Role in Alzheimer's Disease:
|
Improve cognition.
|
|
Pharmacological Role:
|
A long-acting cholinesterase inhibitor.
|
|
Side Effects:
|
Mild, with agitation, insomnia, nausea, and dizziness
described at different rates, slightly more than placebo
group.
|
|
Evidence pro its efficacy:
|
Short-term, Phase III, randomized, double-blind, placebo-
controlled, parallel group study showed significant
improvement in ADAS-Cog to 25 weeks.
|
|
Evidence con its efficacy:
|
Eptastigmine did not provide any protection against sarin
toxicity.
|
|
Dosage:
|
40-60 mg/day investigated
|
|
Companies:
|
Mediolanum Pharmaceuticals
|
|
Notes:
|
The adverse hematologic (granulocytopenia) effects
reported in two studies have resulted in the suspension of
further clinical trials for eptastigmine.
|
Braida D, Sala M. Eptastigmine: ten years of pharmacology,
toxicology, pharmacokinetic, and clinical studies. CNS
Drug Rev. 2001 Winter;7(4):369-86. Abstract
Imbimbo BP, Troetel WM, Martelli P, Lucchelli F. A 6-
month, double-blind, placebo-controlled trial of
eptastigmine in Alzheimer's disease. Dement Geriatr Cogn
Disord. 2000 Jan-Feb;11(1):17-24. Abstract
Imbimbo BP, Martelli P, Troetel WM, Lucchelli F, Lucca U,
Thal LJ. Efficacy and safety of eptastigmine for the
treatment of patients with Alzheimer's disease.
Neurology. 1999 Mar 10;52(4):700-8. Abstract
Imbimbo BP, Verdelli G, Martelli P, Marchesini D. Two-year
treatment of Alzheimer's disease with eptastigmine. The
Eptastigmine Study Group. Dement Geriatr Cogn Disord. 1999
Mar-Apr;10(2):139-47. Abstract
Mant T, Troetel WM, Imbimbo BP. Maximum tolerated dose and
pharmacodynamics of eptastigmine in elderly healthy
volunteers. J Clin Pharmacol. 1998 Jul;38(7):610-7.
Abstract
Canal N, Imbimbo BP. Relationship between pharmacodynamic
activity and cognitive effects of eptastigmine in patients
with Alzheimer's disease. Eptastigmine Study Group. Clin
Pharmacol Ther. 1996 Aug;60(2):218-28. Abstract
|
|
|
|
|
Home
